<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39427065</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>In vitro analysis suggests that SARS-CoV-2 infection differentially modulates cancer-like phenotypes and cytokine expression in colorectal and prostate cancer cells.</ArticleTitle><Pagination><StartPage>24625</StartPage><MedlinePgn>24625</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24625</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75718-1</ELocationID><Abstract><AbstractText>The coronavirus disease 2019 (COVID-19) reportedly exacerbates cancer outcomes. However, how COVID-19 influences cancer prognosis and development remains poorly understood. Here, we investigated the effect of Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), the etiological agent of COVID-19, on cellular cancer phenotypes the expression of cancer-related markers, and various proinflammatory cytokines. We infected prostate (22RV1) and colorectal (DLD-1) cancer cell lines, which express angiotensin-converting enzyme 2 (ACE2), with spike pseudovirus (sPV) and laboratory stocks of live SARS-CoV-2 viruses. After infection, we quantified changes in the cellular cancer phenotypes, the gene expression levels of some cancer markers, including Ki-67, BCL-2, VIM, MMP9, and VEGF, and proinflammatory cytokines. Phenotypic analysis was performed using MTT and wound healing assays, whereas gene expression analysis was carried out using real-time quantitative PCR (RT-qPCR). We show that SARS-CoV-2 infection impacts several key cellular pathways involved in cell growth, apoptosis, and migration, in prostate and colorectal cancer cells. Our results suggest that SARS-CoV-2 infection does influence various cancer cellular phenotypes and expression of molecular cancer markers and proinflammatory cytokines, albeit in a cell-type-specific manner. Our findings hint at the need for further studies and could have implications for evaluating the impact of other viruses on cancer progression.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serwaa</LastName><ForeName>Alberta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry, Cell, and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oyawoye</LastName><ForeName>Fatima</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owusu</LastName><ForeName>Irene Amoakoh</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dosoo</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manu</LastName><ForeName>Aaron Adom</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry, Cell, and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobo</LastName><ForeName>Augustine Kojo</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry, Cell, and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fosu</LastName><ForeName>Kwadwo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry, Cell, and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olwal</LastName><ForeName>Charles Ochieng</ForeName><Initials>CO</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry, Cell, and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quashie</LastName><ForeName>Peter Kojo</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana. pquashie@ug.edu.gh.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK. pquashie@ug.edu.gh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aikins</LastName><ForeName>Anastasia Rosebud</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), College of Basic and Applied Sciences, University of Ghana, Accra, Ghana. araikins@ug.edu.gh.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry, Cell, and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana. araikins@ug.edu.gh.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>INV-036307</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>WACCBIP+NCDs: Awandare</GrantID><Agency>World Bank Group</Agency><Country /></Grant><Grant><GrantID>WAGMC: Ofori-Aquah</GrantID><Agency>World Bank Group</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="Y">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Cytokine expression</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Spike pseudovirus</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39427065</ArticleId><ArticleId IdType="pmc">PMC11490510</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75718-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75718-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bennett, J. E. et al. NCD Countdown 2030: Worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet392, 1072–1088 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30264707</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Closas, M., Gunsoy, N. B. &amp; Chatterjee, N. Combined associations of genetic and environmental risk factors: Implications for prevention of breast cancer. JNCI Comment.106, 1–6 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4271030</ArticleId><ArticleId IdType="pubmed">25392194</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackadar, C. B. WJ CO. World J Clin Oncol7, 54–86 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4734938</ArticleId><ArticleId IdType="pubmed">26862491</ArticleId></ArticleIdList></Reference><Reference><Citation>Krump, N. A. &amp; You, J. Molecular mechanisms of viral oncogenesis in humans. Nat. Rev. Microbiol.16, 684–698 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6336458</ArticleId><ArticleId IdType="pubmed">30143749</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Donnell, J. S., Teng, M. W. L. &amp; Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol.16, 151–167 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30523282</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, J. et al. SARS-CoV-2 cell tropism and multiorgan infection. Cell Discov.7, 2–5 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7987126</ArticleId><ArticleId IdType="pubmed">33758165</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein, S. R. et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature612, 758–763 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. PNAS117, 11727–11734 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260975</ArticleId><ArticleId IdType="pubmed">32376634</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai, Y. et al. A profiling analysis on the receptor ACE2 expression reveals the potential risk of different type of cancers vulnerable to SARS-CoV-2 infection. Ann. Transl. Med8, 481 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7210193</ArticleId><ArticleId IdType="pubmed">32395525</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren, P., Gong, C. &amp; Ma, S. Evaluation of COVID-19 based on ACE2 expression in normal and cancer patients. Open Med.15, 613–622 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7712168</ArticleId><ArticleId IdType="pubmed">33336018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravaioli, S. et al. ACE2 and TMPRSS2 potential involvement in genetic susceptibility to SARS-COV-2 in cancer patients. Cell Transplantatiom29, 1–12 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7593730</ArticleId><ArticleId IdType="pubmed">33108902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang, T., Nguyen, T. Q. &amp; Tran, T. T. A. Genetic susceptibility of ace2 and tmprss2 in six common cancers and possible impacts on covid-19. Cancer Res. Treat.53, 650–656 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8291170</ArticleId><ArticleId IdType="pubmed">33421977</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi, S. et al. Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma. JRAAS J. Renin Angiotensin Aldosterone Syst.13, 202–209 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22048948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling, J., Peng, N. &amp; Luo, L. ACE2 maybe serve as a prognostic biomarker in breast invasive carcinoma. J. Clin. Lab. Anal.36, 1–13 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9169220</ArticleId><ArticleId IdType="pubmed">35373393</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, J. et al. The ACE2/Angiotensin-(1–7)/Mas receptor axis: pleiotropic roles in cancer. Front. Physiol.8, 1–8 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5420593</ArticleId><ArticleId IdType="pubmed">28533754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Q. et al. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. J. Exp. Clin. Cancer Res.38, 1–12 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482513</ArticleId><ArticleId IdType="pubmed">31023337</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, S. et al. Biochemical and biophysical research communications Ang- (1–7) promotes the migration and invasion of human renal cell carcinoma cells via Mas-mediated AKT signaling pathway. Biochem. Biophys. Res. Commun.460, 333–340 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25783053</ArticleId></ArticleIdList></Reference><Reference><Citation>Almutlaq, M., Alamro, A. A., Alamri, H. S., Alghamdi, A. A. &amp; Federico, A. The effect of local renin angiotensin system in the common types of cancer. Front. Endocrinol. (Lausanne)12, 1–18 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8446618</ArticleId><ArticleId IdType="pubmed">34539580</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdecchia, P., Cavallini, C., Spanevello, A. &amp; Angeli, F. European Journal of Internal Medicine The pivotal link between ACE2 de fi ciency and SARS-CoV-2 infection. Eur. J. Intern. Med.76, 14–20 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167588</ArticleId><ArticleId IdType="pubmed">32336612</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha, A. &amp; Anirvan, P. Cancer progression in COVID-19: Integrating the roles of renin angiotensin aldosterone system, angiopoietin-2, heat shock protein-27 and epithelial mesenchymal transition. ecancer14, 1099 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7532023</ArticleId><ArticleId IdType="pubmed">33082849</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao, R., Hernandez, K., Huang, L. &amp; Luke, J. J. ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: Implications for SARS-CoV-2 COVID-19. J. Immunother. Cancer8, 1–14 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7372174</ArticleId><ArticleId IdType="pubmed">32675312</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, P., Li, W., Xie, J., Hou, Y. &amp; You, C. Clinica chimica acta cytokine storm induced by SARS-CoV-2. Clin. Chim. Acta509, 280–287 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283076</ArticleId><ArticleId IdType="pubmed">32531256</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouras, E. et al. Circulating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis. BMC Med.20, 1–15 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8750876</ArticleId><ArticleId IdType="pubmed">35012533</ArticleId></ArticleIdList></Reference><Reference><Citation>Manu, A. A. et al. Heliyon development and utility of a SARS-CoV-2 pseudovirus assay for compound screening and antibody neutralization assays. Heliyon10, e31392 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11141373</ArticleId><ArticleId IdType="pubmed">38826759</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai, Y.-J. et al. A profiling analysis on the receptor ACE2 expression reveals the potential risk of different type of cancers vulnerable to SARS-CoV-2 infection. Ann. Transl. Med.8, 481–481 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7210193</ArticleId><ArticleId IdType="pubmed">32395525</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L. et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann. Oncol.31, 894–901 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270947</ArticleId><ArticleId IdType="pubmed">32224151</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyerstedt, S., Casaro, E. B. &amp; Rangel, É. B. COVID-19: Angiotensin-converting enzyme 2 ( ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur. J. Clin. Microbiol. Infect. Dis.2, 905–919 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7778857</ArticleId><ArticleId IdType="pubmed">33389262</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, L. et al. Proteome-wide data analysis reveals tissue-specific network associated with. J. Mol. Cell Biol.12, 946–957 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454804</ArticleId><ArticleId IdType="pubmed">32642770</ArticleId></ArticleIdList></Reference><Reference><Citation>van Sluijs, L., Pijlman, G. P. &amp; Kammenga, J. E. Why do individuals differ in viral susceptibility? A story told by model organisms. Viruses9, 1–13 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5691635</ArticleId><ArticleId IdType="pubmed">28973976</ArticleId></ArticleIdList></Reference><Reference><Citation>Juríková, M., Danihel, Ľ, Polák, Š &amp; Varga, I. Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer. Acta Histochem.118, 544–552 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27246286</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinnasamy, S., Zameer, F. &amp; Muthuchelian, K. Molecular and biological mechanisms of apoptosis and its detection techniques. J. Oncol. Sci6, 49–64 (2020).</Citation></Reference><Reference><Citation>Hata, A. N., Engelman, J. A. &amp; Faber, A. C. The BCL2 family: Key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov.5, 475–487 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4727530</ArticleId><ArticleId IdType="pubmed">25895919</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, B. D. et al. SARS—CoV—2 spike protein inhibits growth of prostate cancer: A potential role of the COVID-19 vaccine killing two birds with one stone. Med. Oncol.39, 1–7 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8775145</ArticleId><ArticleId IdType="pubmed">35059896</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahlmann, N. A. et al. In vitro analysis of the effect of SARS-CoV-2 Non-VOC and four variants of concern on MHC- class-I expression on Calu-3 and Caco-2 Cells †. Genes14, 1–9 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10378856</ArticleId><ArticleId IdType="pubmed">37510253</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciszewski, W. M., Wozniak, L. A. &amp; Sobierajska, K. SARS-CoV-2 S and N protein peptides drive invasion abilities of colon cancer cells through TGF-β1 regulation. Biochim. Biophys. Acta Mol. Cell Res.1870, 119541 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37468071</ArticleId></ArticleIdList></Reference><Reference><Citation>Fara, A., Mitrev, Z., Rosalia, R. A. &amp; Assas, B. M. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biol.10, 200160 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536084</ArticleId><ArticleId IdType="pubmed">32961074</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, P., Li, W., Xie, J., Hou, Y. &amp; You, C. Cytokine storm induced by SARS-CoV-2. Clin. Chim. Acta509, 280–287 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283076</ArticleId><ArticleId IdType="pubmed">32531256</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnquist, C., Ryan, B. M., Horikawa, I., Harris, B. T. &amp; Harris, C. C. Cytokine storms in cancer and COVID-19. Cancer Cell38, 598–601 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7531591</ArticleId><ArticleId IdType="pubmed">33038939</ArticleId></ArticleIdList></Reference><Reference><Citation>Heydarian, M., Mohammadtaghizadeh, M. &amp; Shojaei, M. The effect of COVID - 19 derived cytokine storm on cancer cells progression: Double—edged sword. Mol. Biol. Rep.49, 605–615 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8520341</ArticleId><ArticleId IdType="pubmed">34657251</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarty, D. et al. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Commun. Biol.3, 374 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7343823</ArticleId><ArticleId IdType="pubmed">32641750</ArticleId></ArticleIdList></Reference><Reference><Citation>Csiszar, A. et al. The pattern of cytokine gene expression. Pathol. Oncol. Res.10, 109–116 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15188028</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, B., Huang, S. &amp; Yin, L. The cytokine storm and COVID-19. J. Med. Virol.93, 250–256 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, Y. et al. Cytokine storm in COVID-19: The current evidence and treatment strategies. Front. Immunol.11, 1708 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7365923</ArticleId><ArticleId IdType="pubmed">32754163</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y. http://www.bio-protocol.org/e86 Vol 1, Iss 7, Mar 05, 2011. bio-protocol1, 5–7 (2011).</Citation></Reference><Reference><Citation>Davarinejad, H. Quantifications of Western Blots with ImageJ (University of York, 2015).</Citation></Reference><Reference><Citation>Pijuan, J. et al. In vitro cell migration, invasion, and adhesion assays: From cell imaging to data analysis. Front. Cell Dev. Biol.7, 1–17 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6587234</ArticleId><ArticleId IdType="pubmed">31259172</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida, V. M. &amp; Amorim, L. M. F. Anticancer drug screening: Standardization of in vitro wound healing assay. J. Bras. Patol. Med. Lab.55, 606–612 (2019).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>